About BYOMASS INC
BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily for the treatment of orphan and common diseases with high unmet medical need.
Development of novel biologic and small molecule drugsPrecision medicine approach targeting specific TGF-β superfamily membersPreclinical to clinical translation using plasma biomarkersDesign of clinical development plans for early efficacy signals in Phase 1 trialsFocus on orphan drug, specialty-focused, and general medicine indications
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to BYOMASS INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.